Avelumab in Merkel Cell Carcinoma: Mechanism, Clinical Evidence, and Risk Considerations

From General Health Science to Occupational Exposure Concerns

The legacy of general health and science information has long emphasized broad public awareness of environmental factors and their potential links to disease. Within this framework, discussions of carcinogen exposure have typically focused on lifestyle choices or ubiquitous pollutants, providing a foundation for understanding risk without delving into specific pathological mechanisms. This heritage naturally extends to occupational settings, where workers may encounter substances with established or emerging health implications. In the context of mass production, particularly in industries involving chemical processing or material handling, the potential for sustained exposure to certain agents becomes a critical consideration. One such area of interest involves the relationship between occupational contact with specific compounds and the subsequent development of rare skin cancers, such as Merkel cell carcinoma. While the general health narrative has historically addressed sun exposure as a primary risk factor, the transition to an occupational exposure concern requires a shift in focus toward workplace environments where dermal or inhalational contact with industrial substances may occur. This pivot acknowledges that workers in manufacturing sectors could face distinct exposure profiles that warrant careful monitoring and risk assessment, moving beyond generalized health advice to targeted occupational health surveillance. The bridge from broad health education to specific workplace hazards thus necessitates a nuanced understanding of how production processes might introduce unique carcinogenic risks, without prematurely attributing mechanistic pathways.

Avelumab: Mechanism of Action and Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was the first therapeutic agent specifically approved for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and highly aggressive skin cancer with neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). In Europe, approved systemic therapies are limited to the PD-L1 inhibitor avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). Despite advances in systemic therapy options for MCC, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). The mechanism of action of avelumab involves blocking PD-L1 on tumor cells and immune cells, thereby preventing the PD-1/PD-L1 interaction that suppresses T-cell activity. This restores antitumor immune responses.

Clinical Evidence and Risk Context for Avelumab in MCC

Checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; the hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who become refractory to avelumab, alternative treatment options are limited. A multicenter study of the prospective skin cancer registry ADOREG evaluated ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). At three different sites in Germany, clinical and molecular data of patients with metastatic MCC refractory to avelumab and later treated with combined ipilimumab/nivolumab were retrospectively collected (https://pubmed.ncbi.nlm.nih.gov/33439294/). Five patients were enrolled, and three out of five responded to combined ipilimumab/nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A separate retrospective study also examined ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC, noting that immune checkpoint inhibitors offer durable responses and significant clinical benefit, with avelumab and pembrolizumab currently approved by the U.S. Food and Drug Administration for the treatment of advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). From a risk perspective, the timeline between avelumab exposure and documented health outcomes is informed by clinical trial data and case reports. In the JAVELIN Merkel 200 trial, objective responses were observed during treatment, and immune-related adverse events can occur at any point during therapy. The case of hypercalcemia due to sarcoidosis reactivation occurred during avelumab treatment and was managed without discontinuation of therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who progress on avelumab, subsequent treatment with ipilimumab plus nivolumab may provide benefit, as evidenced by the retrospective studies (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, avelumab is a PD-L1 inhibitor approved for metastatic MCC based on response rates from a phase II trial. Its mechanism involves immune checkpoint blockade, which can lead to immune-related adverse events. For patients who become refractory, combination therapy with ipilimumab and nivolumab has shown activity. The evidence supports avelumab as a first-line systemic therapy for metastatic MCC, with careful monitoring for irAEs and consideration of alternative checkpoint inhibitor combinations upon progression.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the mechanism of action of avelumab in Merkel cell carcinoma?

Avelumab is a fully human IgG1 monoclonal antibody that targets programmed cell death ligand 1 (PD-L1) on tumor cells and immune cells. By blocking the PD-1/PD-L1 interaction, it prevents the suppression of T-cell activity, thereby restoring antitumor immune responses. This immune checkpoint inhibition has shown efficacy in metastatic Merkel cell carcinoma, with response rates up to 62% in some studies (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

What are the common adverse events associated with avelumab therapy?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system. These may include dermatitis, colitis, hepatitis, pneumonitis, and endocrinopathies. One reported case involved hypercalcemia secondary to reactivation of sarcoidosis, which was managed with corticosteroids without discontinuing avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). Patients require careful monitoring for irAEs during treatment.

What treatment options are available for patients with avelumab-refractory Merkel cell carcinoma?

For patients who progress on avelumab, combination therapy with ipilimumab and nivolumab has shown activity. A retrospective study of five patients with avelumab-refractory MCC found that three out of five responded to combined ipilimumab/nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another study also noted durable responses with this combination in anti-PD-L1/PD-1 refractory MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.